key: cord-0967662-oyroi99a authors: Isaac, Barney Thomas Jesudason; Priya, Nadesan; Nair, Avinash Anil; Thangakunam, Balamugesh; Balachandran, Amith; George, Tina; Thomas, Sheba Meriam; George, Tarun Kottukulam; Iyadurai, Ramya; Kumar, Selwyn Selva; Zachariah, Anand; Singh, Bhagteshwar; Rupali, Priscilla; Pichamuthu, Kishore; Gupta, Richa; Daniel, Jefferson; Sasikumar, Jebin Roger; Chandy, Sujith Thomas; Christopher, Devasahayam Jesudas title: Treatment of COVID-19 ARDS with a tabletop NIV device in a Respiratory Intermediate Care Unit date: 2022-04-19 journal: Mayo Clin Proc Innov Qual Outcomes DOI: 10.1016/j.mayocpiqo.2022.04.001 sha: 9e05a750c53ac1678b39fe7be45501c742b53310 doc_id: 967662 cord_uid: oyroi99a Objective To study the outcome of non-invasive ventilation (NIV) administered through a tabletop device for COVID-19 acute respiratory distress syndrome (ARDS) in a respiratory intermediate care unit (RIMCU) in a tertiary care hospital in India. Patients and methods We retrospectively studied a cohort of patients who received protocolised management with positive airway pressure using a tabletop NIV device in the RIMCU as a step-up rescue therapy, for hospitalised patients deteriorating despite low flow oxygen support. Treatment was commenced on CPAP mode up to a pressure of 10 cm H2O and if required inspiratory pressures were added with BPAP mode. Success was defined as weaning from NIV and stepping down to the ward and failure as escalation to the intensive care unit (ICU) or need for intubation or death. Results In all, 246 patients were treated in the RIMCU during the study period. Of these, 168 received respiratory support via tabletop NIV device as a step-up rescue therapy. Their mean age was 54 years, and 83% were males. Diabetes Mellitus (78%) and hypertension (44%) were the commonest comorbidities. Treatment was successful with tabletop NIV in 77%; of this, 41% on treatment with CPAP alone and 36% after receiving additional increased inspiratory pressures on BPAP mode. Conclusion Respiratory support using a tabletop NIV device was an effective, and economical treatment for CARDS. Further studies are required to assess the appropriate time of initiation for maximal benefit and judicious resource utilisation. COVID-19, caused by SARS COV2 has ravaged the world, not only on account of the large number of individuals infected, but also with regards to the mortality, mostly from respiratory failure. In nearly 81% of symptomatic patients, the disease is mild, and these individuals are likely to get better without any specific measures 1 . Around 14% have moderate symptoms and need hospitalization due to hypoxia but not intensive care unit (ICU) care. However, an additional 5% may require care in ICU due to refractory hypoxia or multiorgan failure 1 . The need for invasive mechanical ventilation (IMV) in those who are critically ill is high. The outcomes with IMV were abysmal from initial reports. In a report from 552 hospitals across China, 2 the mortality rate of those on IMV was 60% (assuming all who died in hospital were ventilated). This is despite onefifth receiving ECMO. In 2 subsequent reports from China, the mortality among those on IMV was 86% 3 and 97% 4 . Reports from 2 large cohorts from New York 5 and the UK 6 , showed better outcomes, with a mortality of 24.5% and 37% in those who received IMV, however, it has to be kept in mind that 72% and 46% patients respectively remained in hospital at the time of reporting. Non-invasive respiratory support strategies are an attractive option to avoid the need for IMV and its inherent risks. 7 India's first wave commenced in March 2020 and as the case numbers surged by July 2020, our hospital resources were stretched. There was a woeful shortage of critical care beds. The J o u r n a l P r e -p r o o f respiratory medical ward was converted into a 14-bedded RIMCU to address the need. Each bed was provided with a multiparameter monitor capable of continuously monitoring oxygen saturation, heart rate and respiratory rate. The RIMCU was air-conditioned, and negative pressure was set up to ensure 12 air exchanges per hour to improve the safety of the health care workers. The patient to respiratory therapist, nurse and doctor ratio were 1:5, 1:3 and 1:5 respectively. The service was designed for RT-PCR proven COVID-19 patients with worsening respiratory status from the COVID wards and from the emergency department. They were accepted if they fulfilled the following criteria: a) oxygen requirement of more than 40% via venturi mask or more than 5 L/min through nasal prongs to maintain target SpO2 of ≥ 92%, and/or b) increased work of breathing as indicated by a respiratory rate of >30 breaths/min and use of accessory muscles of respiration. Patients who required more than 60% FiO2 to maintain target saturation, those with impending respiratory arrest and those with absolute contraindications for NIV, were not received into RIMCU and were admitted directly to the ICU. A few patients were stepped down from ICU on NIV for weaning before shift to the medical ward. They were not included in the analysis. With a view to prioritise the available resources to those for whom maximum benefit were likely, escalation plans were drawn out at admission as per the criteria formulated by the COVID clinical treatment group, in consultation with the patient and family. This was based on age, comorbidities among other factors which influence the outcome: -'For full escalation' implied that the plan was to shift to the ICU if the patient deteriorates despite NIV, fulfilling predefined criteria for transfer to ICU. -'NIV as the ceiling of care' implied that the patient would not be transferred to ICU, even if they fulfilled criteria for transfer to ICU, and management would continue in the RIMCU, till they improved or died. A chest x-ray was obtained prior to initiation of NIV, to obtain a baseline assessment of lung infiltrates and to rule out a pneumothorax which is a contraindication for NIV. Positive airway pressure was administered using one of the following tabletop NIV Once a PEEP of 10 cm of H2O was reached and targets were still not met, we switched to BPAP mode, and the inspiratory positive airway pressure (IPAP) was increased gradually by 2 cm of H2O, till targets were met or till a pressure of 20 cm of H2O was reached. The IPAP minus EPAP was the additional pressure support given during inspiration. Low dose sedation with dexmedetomidine was used in some patients who had difficulty tolerating the NIV. Awake selfpositioning was advocated in all, with a 2-hour position change calendar, assisted by the nurses and the respiratory therapists. J o u r n a l P r e -p r o o f Though oxygen can be delivered through the circuit of these tabletop NIV devices, due to the absence of an oxygen blender, the delivered FiO2 is unknown. Therefore, we conducted experiments with a test lung and an FiO2 meter which resulted in the creation of an FiO2 chart (table 1) . We used this to estimate the delivered FiO2, thus facilitating titration of oxygen administration and the SF (SpO2/FiO2) and PF (PaO2/FiO2) ratios were calculated. Once stabilised, the pressures were progressively reduced and if on BPAP mode, a switch was made to CPAP mode and if stable for at least 24 hours, protocolized weaning was initiated - A total of 246 patients with CARDS were managed in the RIMCU during the study Within the tabletop NIV device, since our algorithm involved initiation of treatment with CPAP mode initially and only if required a stepping up to receive higher inspiratory pressures via BPAP mode, we were able to look at the success of these modes ( fig. 4) . 4 ). When we faced a surge of patients hospitalised for oxygen therapy in COVID medical wards, some of whom worsened, requiring higher respiratory support, our ICU capacity was overwhelmed. This prompted us to consider the setting up the RIMCU to use tabletop NIV as rescue therapy to avoid ICU care and mechanical ventilation. A systematic review and network meta-analysis 16 in acute hypoxemic respiratory failure, published in 2020, concluded that noninvasive oxygenation strategies compared with standard oxygen therapy was associated with a lower risk of death and lower need for IMV. However, the studies included in this meta-analysis were predominantly on community-acquired pneumonia. In the pre-COVID era, the ERS/ATS clinical practice guidelines 10 published in 2017 cautiously recommend NIV in acute hypoxemic respiratory failure secondary to community-acquired pneumonia or early ARDS. It is proposed as a preventive strategy for avoiding intubation only in a subset of highly selected cooperative patients, when performed by an experienced team in the absence of any major organ dysfunction. It is known that the ARDS lung is stiff, often called the 'baby lung' with poor compliance 17 , often J o u r n a l P r e -p r o o f requiring IMV with strategies of high PEEP, low tidal volumes, permissive hypercapnia, recruitment manoeuvres and prone positioning. However, in the earlier part of COVID-19, the lung appears to be compliant with low elastance, described as the L-type 17 , and hence can generate good volumes; therefore it is likely to be amenable to NIV. If it progresses, then the compliance decreases in later stages, with high elastance, when it is called H-type 17 ARDS, which behaves like conventional non-COVID ARDS and is more likely to require IMV. In our cohort, the success rate of the tabletop NIV device was 77% (129 out of 168) in CARDS. This is higher than most published studies that have used CPAP or BPAP in COVID19, which have reported success rates ranging from 33% to 70%. [18] [19] [20] [21] [22] [23] [24] We believe that 4 factors could have played a role in the good success in our cohort: timely initiation of NIV, dedicated NIV ward(RIMCU) & skilled workforce experienced in administering NIV treatment, the addition of pressure support beyond just CPAP and the use of awake self-proning. While the role of NIV in the management of CARDS is becoming increasingly recognised, the time of initiation and the mode of delivery is yet to be established. Our experience is consistent with the advantage of early initiation of CPAP as reported by researchers from the UK 13, 14 . We hypothesise that the early initiation of respiratory support could prevent the patient self-inflicted lung injury (P-SILI) which is initiated and propagated by massive unsupported inspiratory efforts by these patients. This has been previously proposed 25 for spontaneously breathing CARDS patients. A recent simulation study 26 with mathematical computation showed that P-SILI is comparable to ventilatory induced lung injury. Hence, we used the requirement of either supplemental oxygen or work of breathing to select suitable patients. Setting up of a dedicated area (RIMCU), with adequate monitoring devices and deployment of adequately skilled workforce -doctors, nurses, and respiratory therapists -round the clock, was key to our success. The success of similar models has been reported by Since COVID-19 results in a hypoxemic respiratory failure, most experts believe only CPAP or PEEP alone is beneficial, as it helps in keeping the alveoli open during expiration and enhances oxygenation; this has resulted in most NIV trials in COVID-19 using only CPAP. [18] [19] [20] [21] [22] [23] [24] 27, 28 However, another aspect of CARDS is an increased work of breathing. While it is true that the splinting effect of the PEEP can partly take care of this, we hypothesised that adding pressure support may have a role in those who fail CPAP. In our cohort, the success of CPAP mode alone was 41% which is comparable to some of the other reports that have used the CPAP mode alone. [18] [19] [20] [21] [22] [23] [24] However, by adding pressure support via BPAP mode our success increased by 36%, resulting in an overall success of 77% for the tabletop NIV. Our study has thus demonstrated the merit of this strategy. We would like to propose the following explanation for the benefit of adding pressure support via BPAP mode over CPAP, in those who fail the latter. Adding pressure support decreases the work of breathing. It also increases the minute ventilation, which in turn increases the alveolar ventilation when the respiratory rate is not further increased (minute ventilation = tidal volume x respiratory rate; alveolar ventilation = tidal volume -anatomic dead space ). The increase in alveolar ventilation would result in increase in oxygenation. On the contrary, higher the pressure, lower will be the FiO2 for the same flow of oxygen ( NIV through a tabletop device is a safe, effective, and affordable treatment for COVID-19 ARDS and is likely to prevent the need for ICU care, invasive ventilation and possibly mortality, in hospitalised patients deteriorating despite low flow oxygen support. An exclusive setup with adequate monitoring may be essential for optimal outcome. Further studies are required to confirm the appropriate time for initiation of NIV for maximal benefit and judicious resource utilisation. -6 21 30 38 52 59 71 85 97 -8 21 27 35 46 47 62 65 80 -10 21 26 32 40 46 50 55 67 -12 21 25 32 37 42 46 48 58 16 10 21 26 31 37 42 48 52 61 J o u r n a l P r e -p r o o f 18 10 21 26 30 34 39 44 48 57 20 10 21 25 29 33 37 42 46 54 *All measurements done with oxygen entry closer to the mask and away from the exhalation port as seen in figure 1 FiO2 = fraction of inspired oxygen IPAP = inspiratory positive airway pressure in cm of H2O EPAP = expiratory positive airway pressure in cm of H2O = PEEP (positive end expiratory pressure) IPAP -EPAP = pressure support Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Clinical Characteristics of Coronavirus Disease 2019 in China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study Non-invasive respiratory support strategies in COVID-19 Non-invasive ventilation in chronic obstructive pulmonary disease: management of acute type 2 respiratory failure Non-invasive ventilation in acute respiratory failure Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure Non-invasive ventilation for obese patients with chronic respiratory failure: Are two pressures always better than one? Respirol Carlton Vic International variation in the management of severe COVID-19 patients Is continuous positive airway pressure (CPAP) a new standard of care for type 1 respiratory failure in COVID-19 patients? A J o u r n a l P r e -p r o o f retrospective observational study of a dedicated COVID-19 CPAP service Reduced critical care demand with early CPAP and proning in COVID-19 at Bradford: a single centre cohor Helmet CPAP to Treat Acute Hypoxemic Respiratory Failure in Patients with COVID-19: A Management Strategy Proposal Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-analysis Management of COVID-19 Respiratory Distress Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study Continuous Positive Airway Pressure (CPAP) facemask ventilation is an easy and cheap option to manage a massive influx of patients presenting acute respiratory failure during the SARS-CoV-2 outbreak: A retrospective cohort study Noninvasive Ventilatory Support of Patients with COVID-19 outside the Intensive Care Units (WARd-COVID) Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study Non-invasive CPAP in mild and moderate ARDS secondary to SARS-CoV-2 Noninvasive respiratory support and patient selfinflicted lung injury in COVID-19: a narrative review High risk of patient self-inflicted lung injury in COVID-19 with frequently encountered spontaneous breathing patterns: a computational modelling study CPAP management of COVID-19 respiratory failure: a first quantitative analysis from an inpatient service evaluation Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial The Add PS* of 6cm (IPAP of 16/EPAP of 10)* increase PS incrementally by 2 cm of H2O to a maximum IPAP of 20 cm of H2O to achieve above targets